Archive · 20 Jan 2026
Zydus Lifesciences Eyes Ardelyx Acquisition for $2.5B
Zydus Lifesciences, a big Indian medicine company, is thinking about buying a large part of Ardelyx, a US company that makes special medicines for stomach and heart problems.
This deal could cost between $2.2 and $2.5 billion.
Zydus plans to use some of its own money and raise more money from investors to pay for it.
Ardelyx is worth about $1.7 billion and made $378 million last year.
Zydus has been buying other companies to grow bigger and sell more kinds of medicines.
Another Indian medicine company, Sun Pharma, is also trying to buy a US company called Organon for $10 billion.
Both companies want to sell more special medicines around the world.
Zydus Lifesciences is evaluating the acquisition of a majority stake in US-based Ardelyx Inc. for $2.2–2.5 billion.
The deal will be funded through a ₹5,000-crore equity raise via QIP and internal cash accruals.
Ardelyx focuses on gastrointestinal and cardio-renal diseases with a market cap of $1.7 billion and 2025 revenue of $378 million.
Zydus has been expanding globally with recent acquisitions in biologics and medical devices.
Zydus had net cash of ₹4,883.6 crore as of 31 March 2025.
- Who
- Zydus Lifesciences and Ardelyx Inc.
- What
- Potential acquisition of a majority stake in Ardelyx by Zydus Lifesciences
- When
- Currently under evaluation (specific timeline not mentioned)
- Where
- Zydus Lifesciences (Ahmedabad, India) and Ardelyx (US)
- Why
- To accelerate Zydus’s push into global innovative medicine and diversify beyond generic drugs
- Company
- Zydus Lifesciences
- Target Company
- Ardelyx Inc.
- Deal Value
- $2.2–2.5 billion
- Funding Sources
- ₹5,000-crore QIP and internal cash
- Ardelyx Market Cap
- $1.7 billion (as of 20 January)
- Ardelyx Revenue (2025)
- $378 million (up 18%)
- Zydus Net Cash (as of 31 March 2025)
- ₹4,883.6 crore